201 related articles for article (PubMed ID: 17468644)
1. Use of meningococcal vaccines in the United States.
Bilukha O; Messonnier N; Fischer M
Pediatr Infect Dis J; 2007 May; 26(5):371-6. PubMed ID: 17468644
[TBL] [Abstract][Full Text] [Related]
2. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Oct; 54(40):1023-5. PubMed ID: 16224452
[TBL] [Abstract][Full Text] [Related]
3. Menactra: a meningococcal conjugate vaccine.
Med Lett Drugs Ther; 2005 Apr; 47(1206):29-31. PubMed ID: 15821633
[TBL] [Abstract][Full Text] [Related]
4. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2005 Aug; 116(2):496-505. PubMed ID: 15995007
[TBL] [Abstract][Full Text] [Related]
5. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Aug; 60(30):1018-9. PubMed ID: 21814165
[TBL] [Abstract][Full Text] [Related]
6. Prevention of meningococcal disease.
Kimmel SR
Am Fam Physician; 2005 Nov; 72(10):2049-56. PubMed ID: 16342836
[TBL] [Abstract][Full Text] [Related]
7. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
[TBL] [Abstract][Full Text] [Related]
8. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4).
Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 May; 57(17):462-5. PubMed ID: 18451758
[TBL] [Abstract][Full Text] [Related]
9. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
[TBL] [Abstract][Full Text] [Related]
10. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Sep; 58(37):1042-3. PubMed ID: 19779400
[TBL] [Abstract][Full Text] [Related]
11. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.
Mehlhorn AJ; Balcer HE; Sucher BJ
Ann Pharmacother; 2006 Apr; 40(4):666-73. PubMed ID: 16595570
[TBL] [Abstract][Full Text] [Related]
12. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Bilukha OO; Rosenstein N;
MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
[TBL] [Abstract][Full Text] [Related]
13. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
14. Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):72-6. PubMed ID: 21270745
[TBL] [Abstract][Full Text] [Related]
15. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(41):1120-4. PubMed ID: 17060898
[TBL] [Abstract][Full Text] [Related]
16. Physician perspectives to inform a new recommendation for meningococcal conjugate vaccine (MCV4).
Clark SJ; Cowan AE; Stokley S; Bilukha O; Davis MM
J Adolesc Health; 2006 Dec; 39(6):850-5. PubMed ID: 17116515
[TBL] [Abstract][Full Text] [Related]
17. Recommended childhood immunization schedule--United States, 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Jan; 50(1):7-10, 19. PubMed ID: 11215789
[TBL] [Abstract][Full Text] [Related]
18. Syncope after vaccination--United States, January 2005-July 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 May; 57(17):457-60. PubMed ID: 18451756
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal conjugate vaccination among adolescents aged 13-17 years, United States, 2007.
Lu PJ; Jain N; Cohn AC
Vaccine; 2010 Mar; 28(11):2350-5. PubMed ID: 20044055
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry.
Enger KS; Stokley S
J Adolesc Health; 2007 May; 40(5):398-404. PubMed ID: 17448396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
